Vimarsana
Biggest News Aggregation in the World

Page 2 - Validus Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Validus Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Validus Pharmaceuticals Today - Breaking & Trending Today

Acromegaly Market size 2023, recent trends, business opportunity, share and forecast to 2031 - Vimarsana News

Acromegaly Market size 2023, recent trends, business opportunity, share and forecast to 2031

According to the deep-dive market assessment study by Growth Plus Reports, the global acromegaly market was valued at US$ 1.56 billion in 2022 and is expected to register a revenue CAGR of 7.7% to reach US$ 3.04 billion by 2031.

Diuretic Drugs Market size to grow by USD 95.64 million from 2021 to 2026, Driven by the increasing incidence of hypertension among people - Vimarsana News

Diuretic Drugs Market size to grow by USD 95.64 million from 2021 to 2026, Driven by the increasing incidence of hypertension among people

/PRNewswire/ -- The diuretic drugs market size is forecasted to increase by USD 95.64 million from 2021 to 2026, at a CAGR of 5.44%, according to the recent...

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha - Vimarsana News

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha

ANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative...

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials - Vimarsana News

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

/PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL)...

Glenmark Pharmaceuticals launches Bumetanide Injection - Vimarsana News

Glenmark Pharmaceuticals launches Bumetanide Injection

Glenmark Pharmaceuticals Inc., USA has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex® Injection.